Therapy of benign prostatic hyperplasia: terazosin or finasteride?
Trinkler, F.B.
Praxis 86(34): 1305-1306
1997
ISSN/ISBN: 1661-8157 PMID: 9381019 Document Number: 471814
Document emailed within 1 workday
Related Documents
Anwarul Islam, A.K.M.; Kashem, M.A.; Shameem, I.A.; Kibria, S.A.M.G. 2005: Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: a comparative study Bangladesh Medical Research Council Bulletin 31(2): 54-61Granados Loarca, E.A. 1999: Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume Archivos Espanoles de Urologia 52(3): 201-208
Ekman, P.; Andersen, J.T.; Wolf, H. 1996: Finasteride in the treatment of benign prostatic hyperplasia Acta Urologica Belgica 64(1): IX-XII
Wu, T.T.; Lee, Y.H.; Jiaan, B.P.; Huang, J.K. 1995: The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia Zhonghua Yi Xue Za Zhi 56(6): 399-403
Dogra, P.N.; Biswas, N.R.; Ravi, A.K.; Mani, K.; Kumar, V. 2005: Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia Journal of the Indian Medical Association 103(2): 108
Magoha, G.A. 1998: Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia East African Medical Journal 75(5): 260-263
Tveter, K.J.; Beisland, H.O.; Andersen, J.T.; Wolf, H.; Ekman, P.; Johansson, J.E.; Kontturi, M.; Lehtonen, T. 1996: Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 116(27): 3226-3230
Jonas, U.; Melchior, H.; Rübben, H. 1998: Recommendations for billing alternative therapy of benign prostatic hyperplasia. Laser therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 37(1): 110-111
Yu, H.J.; Chiu, T.Y.; Lai, M.K. 1995: Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial Journal of the Formosan Medical Association 94(1-2): 37-41
Denti, L.; Pasolini, G.; Cortellini, P.; Sanfelici, L.; Benedetti, R.; Cecchetti, A.; Ferretti, S.; Banchini, A.; Ablondi, F.; Valenti, G. 1999: Effects of 5 alpha-reductase inhibition by finasteride on lipoproteins and body composition in males affected by benign prostatic hyperplasia (BPH) Journal of Endocrinological Investigation 22(10 Suppl): 70-71
Ekman, P. 1992: Drug therapy of benign prostatic hyperplasia Lakartidningen 89(45): 3803-3804
Goldfarb, B.; Bartkiw, T.; Trachtenberg, J. 1995: Microwave therapy of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 431-439
Madersbacher, S.; Marberger, M. 1996: Minimal invasive therapy of benign prostatic hyperplasia Wiener Medizinische Wochenschrift 146(8): 169-175
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Hanus, M.; Matousková, M. 1993: Antiestrogens (tamoxifen) in the alternative therapy of benign prostatic hyperplasia Rozhledy V Chirurgii: Mesicnik Ceskoslovenske Chirurgicke Spolecnosti 72(7): 316-318
Savage, S.J..; Spungen, A.M..; Galea, G.; Britanico, J.; Vapnek, J.M.. 1998: Combination medical therapy for symptomatic benign prostatic hyperplasia Canadian Journal of Urology 5(3): 578-584
Drsata, J. 2002: Enzyme inhibition in the drug therapy of benign prostatic hyperplasia Casopis Lekaru Ceskych 141(20): 630-635
Effert, P.; Ackermann, R. 1992: Clinical manifestations and indications for therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 31(3): 135-141
Larosa, M.; Ferretti, S.; Salsi, P.; Simonazzi, M. 1994: Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience Acta Bio-Medica de l'Ateneo Parmense 65(1-2): 23-28
Nadeem, H.M.R.; Mohiuddin, E.; UdDin, S.; Daniyal, M.; Usmanghani, K. 2017: Comparison of Anti BPH capsule (herbal) and Terazosin HCl in the treatment of benign prostate hyperplasia Pakistan Journal of Pharmaceutical Sciences 30(1 Suppl): 289-293